Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  CNS Drugs

• Publication date

  2015-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40263-015-0227-1PMID 25666445
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

  2015influential reference
• Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

  2014influential reference
• Emerging injectable therapies for multiple sclerosis.

  2013cited by this paper
• Systematic Literature Review and Meta-analysis

  2013influential reference
• Multiple sclerosis.

  2012cited by this paper
• A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

  2012influential reference
• PEGylation of Interferon-β-1a

  2012cited by this paper
• Multiple sclerosis review.

  2012cited by this paper
• Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents

  2011cited by this paper
• PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis

  2010influential reference
• Current and Future Directions in MS Management: Key Considerations for Managed Care Pharmacists

  2009cited by this paper
• PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies

  2007cited by this paper
• Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

  2001cited by this paper

• Engineering neuroimmune regulation: biomaterial and nanotechnology platforms for neuropathology diagnosis and targeted immunomodulation

  2026cites this paper
• Molecular Survival Strategies Against Kidney Filtration: Implications for Therapeutic Protein Engineering

  2026cites this paper
• Advances in conjugate drug delivery System: Opportunities and challenges.

  2024cites this paper
• Approved delivery strategies for biopharmaceuticals

  2024cites this paper
• Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)

  2024cites this paper
• An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis

  2023cites this paper
• Review on theranostic and neuroprotective applications of nanotechnology in multiple sclerosis

  2023cites this paper
• Cytokine Therapy

  2021cites this paper
• Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression

  2021cites this paper
• Molecular Simulations of PEGylated Biomolecules, Liposomes, and Nanoparticles for Drug Delivery Applications

  2020cites this paper
• Evolution of polymer conjugation to proteins

  2020cites this paper
• The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules.

  2020cites this paper
• Reduced disease severity following therapeutic treatment with angiotensin 1-7 in a mouse model of multiple sclerosis.

  2019cites this paper
• Gold nanoparticles and polyethylene glycol alleviate clinical symptoms and alter cytokine secretion in a mouse model of experimental autoimmune encephalomyelitis

  2019cites this paper
• Nanomaterials in the Market or in the Way of

  2018cites this paper
• Analyzing PEGylation through Molecular Dynamics Simulations

  2018cites this paper
• Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

  2017cites this paper
• Disease modifying therapies for the treatment of relapse-remitting multiple sclerosis

  2017cites this paper
• Modifying therapies for the treatment of relapse-remitting multiple sclerosis

  2017cites this paper
• Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem

  2016cites this paper
• Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis.

  2016cites this paper
• Drug and protein delivery by polymer conjugation

  2016cites this paper
• Disulfide-bridging PEGylation during refolding for the more efficient production of modified proteins.

  2016cites this paper
• Optimizing novel implant formulations for the prolonged release of biopharmaceuticals using in vitro and in vivo imaging techniques.

  2016cites this paper
• Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU

  2015cites this paper
• Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU

  2015cites this paper